Charles York II Sells 6,065 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles York II sold 6,065 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $70,354.00. Following the completion of the transaction, the chief financial officer owned 312,025 shares in the company, valued at approximately $3,619,490. This trade represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Day One Biopharmaceuticals Stock Performance

Shares of Day One Biopharmaceuticals stock opened at $12.07 on Friday. The company has a market cap of $1.24 billion, a P/E ratio of -7.94 and a beta of -1.26. The firm has a fifty day moving average of $10.42 and a two-hundred day moving average of $8.59. Day One Biopharmaceuticals, Inc. has a one year low of $5.64 and a one year high of $13.20.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research report on Monday, December 29th. JPMorgan Chase & Co. lifted their price target on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Piper Sandler upped their price objective on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, November 24th. Finally, TD Cowen initiated coverage on shares of Day One Biopharmaceuticals in a research report on Tuesday, January 13th. They set a “buy” rating and a $34.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $25.71.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Invesco Ltd. boosted its position in shares of Day One Biopharmaceuticals by 26.5% in the 4th quarter. Invesco Ltd. now owns 123,994 shares of the company’s stock worth $1,156,000 after buying an additional 25,952 shares in the last quarter. Oracle Investment Management Inc. acquired a new position in Day One Biopharmaceuticals during the fourth quarter worth about $932,000. XTX Topco Ltd lifted its holdings in shares of Day One Biopharmaceuticals by 62.9% in the fourth quarter. XTX Topco Ltd now owns 128,440 shares of the company’s stock valued at $1,197,000 after purchasing an additional 49,592 shares in the last quarter. VARCOV Co. purchased a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at about $261,000. Finally, Vestal Point Capital LP grew its position in shares of Day One Biopharmaceuticals by 94.4% in the fourth quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock valued at $48,464,000 after purchasing an additional 2,525,000 shares during the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.